Novartis shares tumble after second late-stage drug setback
Novartis shares fell after the company reported a second late-stage clinical setback. Its global Phase III HARBOR study in myotonic dystrophy type 1 (DM1) did not demonstrate a statistic.
The news adds further pressure to the Swiss pharma giant's pipeline after another clinical setback announced the day before. Novartis said its global Phase III HARBOR study of delpacibart etedesiran, or del-desiran, in patients with myotonic dystrophy type 1 (DM1) did not demonstrate a statistic…